Comparison of outcomes in patients in whom the protocol was followed
| Protocol followed | Protocol not followed | P value | |
| n=257 | n=25 | ||
| Male (%) | 78.0% | 96.0% | 0.033 |
| Age (median, IQR) | 35 (25–55) | 36 (27–63) | 0.527 |
| Mechanism (%) | |||
| Blunt | 54.3% | 66.7% | 0.246 |
| Penetrating injury | 45.7% | 33.3% | |
| History of VTE (%) | 1.6% | 0.0% | 0.527 |
| ISS (median, IQR) | 17 (10–26) | 33 (13–35) | 0.032 |
| BMI (median, IQR) | 24.8 (22.1–29.3) | 24.6 (21.9–26.8) | 0.127 |
| ICU length of stay (days; median, IQR) | 4 (2 -7) | 15 (5–25) | <0.001 |
| Hospital length of stay (days; median, IQR) | 10 (6–18) | 26 (17–34) | <0.001 |
| Creatinine clearance (median, IQR) | 126 (99–166) | 116 (72–137) | 0.144 |
| First enoxaparin dose (%) | |||
| 30 mg two times per day | 95.7% | 96.0% | 0.900 |
| 40 mg two times per day | 3.6% | 4.0% | |
| 60 mg two times per day | 0.7% | 0.0% | |
| Hours to enoxaparin initiation (median, IQR) | 31 (16–55) | 28 (19–58) | 0.909 |
| Total anti-Xa levels collected (median, IQR) | 1 (1-2) | 3 (2-3) | <0.001 |
| Dose modifications made (median, IQR) | 0 (0–1) | 1 (0–1) | 0.138 |
| Therapeutic anti-Xa level (%) | 69.4% | 64.0% | 0.577 |
| Final enoxaparin dose (%) | |||
| 30 mg two times per day | 59.6% | 32.0% | 0.032 |
| 40 mg two times per day | 29.0% | 60.0% | |
| 60 mg two times per day | 9.0% | 8.0% | |
| 80 mg two times per day | 1.6% | 0.0% | |
| 100 mg two times per day | 0.8% | 0.0% | |
| Major bleeding (%) | 2.4% | 0.0% | 0.438 |
| Venous thromboembolic events (%) | 8.6% | 16.0% | 0.225 |
| Mortality (%) | 0.8% | 4.0% | 0.136 |
The boldface signifies statistically significant p values <0.05.
BMI, body mass index; ICU, intensive care unit; INR, international normalized ratio; IQR, interquartile range; ISS, Injury Severity Score; VTE, venous thromboembolism.